Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II, Parallel, Randomized, Clinical Trials Comparing the Responses to Initiation of NNRTI-Based Versus PI-Based Antiretroviral Therapy in HIV Infected Infants Who Have and Have Not Previously Received Single Dose Nevirapine for Prevention of Mother-to-Child HIV Transmission
Brief Summary: A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been shown to be an effective way of reducing the risk of mother-to-child transmission (MTCT) of HIV. The purpose of this study was to compare the effectiveness of a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral regimen versus a protease inhibitor (PI)-based regimen in HIV infected infants who had or had not been exposed to SD NVP for prevention of MTCT.

\>\>

\>\> A five year follow up has been added to the study.


Options:
A: Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: nevirapine; Assigned to Arm(s): N/A
C: Arm Label: Coh I: NVP; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine, Drug: Nevirapine, Drug: Zidovudine | Arm Label: Coh I: LPV/r; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine, Drug: Lopinavir/ritonavir, Drug: Zidovudine | Arm Label: Coh II: NVP; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine, Drug: Nevirapine, Drug: Zidovudine | Arm Label: Coh II: LPV/r; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine, Drug: Lopinavir/ritonavir, Drug: Zidovudine | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): Coh I: LPV/r, Coh I: NVP, Coh II: LPV/r, Coh II: NVP | Intervention Type: DRUG; Name: Lopinavir/ritonavir; Assigned to Arm(s): Coh I: LPV/r, Coh II: LPV/r | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): Coh I: NVP, Coh II: NVP | Intervention Type: DRUG; Name: Zidovudine; Assigned to Arm(s): Coh I: LPV/r, Coh I: NVP, Coh II: LPV/r, Coh II: NVP
D: Arm Label: Deferred therapy Arm; Type: EXPERIMENTAL; Interventions: Drug: Abacavir sulfate, Drug: Didanosine, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Zidovudine | Arm Label: Early therapy for 40 weeks; Type: EXPERIMENTAL; Interventions: Drug: Abacavir sulfate, Drug: Didanosine, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Zidovudine | Arm Label: Early therapy for 96 weeks; Type: EXPERIMENTAL; Interventions: Drug: Abacavir sulfate, Drug: Didanosine, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Zidovudine | Intervention Type: DRUG; Name: Abacavir sulfate; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Didanosine; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Zidovudine; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks

Answer: C